Shoshana Revel-Vilk

Prof. Shoshana Revel-Vilk

Shaare Zedek Medical Center
+1
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
NGNeil A. Goldenberg
Neil A. Goldenberg
ASAnthony Sochet
Anthony Sochet
MAManuela Albisetti
Manuela Albisetti
TBTina Biss
Tina Biss
MBMariana Bonduel
Mariana Bonduel
CMChristoph Male
Christoph Male

Verified
Journal Article
Open access
PDF file
Shoshana Revel-VilkShoshana Revel-Vilk
Shoshana Revel-Vilk
Maria FullerMaria Fuller
Maria Fuller
Ari ZimranAri Zimran
Ari Zimran
The challenges in the diagnosis, prognosis, and monitoring of Gaucher disease (GD), an autosomal recessive inborn error of glycosphingolipid metabolism, can negatively impact clinical outcomes. This systematic literature review evaluated the value of glucosylsphingosine (lyso-Gb1), as the most reliable biomarker currently available for the diagnosis, prognosis, and disease/treatment monitoring of patients with GD. Literature searches were conducted using MEDLINE, Embase, PubMed, ScienceOpen, Science.gov, Biological Abstracts, and Sci-Hub to identify original research articles relevant to lyso-Gb1 and GD published before March 2019. Seventy-four articles met the inclusion criteria, encompassing 56 related to pathology and 21 related to clinical biomarkers. Evidence for lyso-Gb1 as a pathogenic mediator of GD was unequivocal, although its precise role requires further elucidation. Lyso-Gb1 was deemed a statistically reliable diagnostic and pharmacodynamic biomarker in GD. Evidence supports lyso-Gb1 as a disease-monitoring biomarker for GD, and some evidence supports lyso-Gb1 as a prognostic biomarker, but further study is required. Lyso-Gb1 meets the criteria for a biomarker as it is easily accessible and reliably quantifiable in plasma and dried blood spots, enables the elucidation of GD molecular pathogenesis, is diagnostically valuable, and reflects therapeutic responses. Evidentiary standards appropriate for verifying inter-laboratory lyso-Gb1 concentrations in plasma and in other anatomical sites are needed.

29 May 2018 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
Shoshana Revel-VilkShoshana Revel-Vilk
Shoshana Revel-Vilk
JSJeff Szer
Jeff Szer
AMAtul Mehta
Atul Mehta
Ari ZimranAri Zimran
Ari Zimran

Verified
Journal Article
Open access
PDF file
NHnoa hurvitz
noa hurvitz
TDTama Dinur
Tama Dinur
MBMichal Becker-Cohen
Michal Becker-Cohen
CCClaudia Cozma
Claudia Cozma
MHMarina Hovakimyan
Marina Hovakimyan
Shoshana Revel-VilkShoshana Revel-Vilk
Shoshana Revel-Vilk
The role of glucosylsphingosine (lyso-Gb1), a downstream metabolic product of glucosylceramide, for monitoring treated and untreated children with Gaucher disease (GD) has not yet been studied. We reviewed the clinical charts of 81 children (<18 years), 35 with mild type 1 GD (GD1), 34 with severe GD1 and 12 with type 3 GD (GD3), followed at Shaare Zedek Medical Center between 2014–2018. Disease severity for GD1 was based on genotypes. Forty children (87%) with severe GD1 and GD3 received enzyme replacement therapy (ERT) compared to two children (6%) with mild GD1. Lyso-Gb1 measurements were conducted on dried blood spot samples taken at each clinic visit. Lyso-Gb1 levels were significantly lower in children with mild compared to severe GD1 (p = 0.009). In untreated children, lyso-Gb1 levels were inversely correlated with platelet counts. During follow-up, lyso-Gb1 increased in almost 50% of untreated children, more commonly in younger children. In treated children, lyso-Gb1 levels were inversely correlated with hemoglobin levels. The increase of lyso-Gb1 while receiving ERT, seen in eight children, was partly associated with compliance and weight gain. Lyso-Gb1 seems to be a useful biomarker for monitoring children with GD and should be included in the routine follow-up. Progressive increase in lyso-Gb1 levels in untreated children suggests ERT initiation.

25 October 2018 in Blood
Verified
Journal Article
Open access
PDF file
Shoshana Revel-VilkShoshana Revel-Vilk
Shoshana Revel-Vilk
ESEla Shai
Ela Shai
ETErnest Turro
Ernest Turro
NJNivin Jahshan
Nivin Jahshan
EHEsti Hi-Am
Esti Hi-Am
MLMichele P. Lambert
Michele P. Lambert

19 February 2021 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
MIMajdolen Istaiti
Majdolen Istaiti
Shoshana Revel-VilkShoshana Revel-Vilk
Shoshana Revel-Vilk
MBMichal Becker‐Cohen
Michal Becker‐Cohen
TDTama Dinur
Tama Dinur
URUma Ramaswami
Uma Ramaswami
Ari ZimranAri Zimran
Ari Zimran